A naukri.com initiative
Bioengineer
3d
95
Image Credit: Bioengineer
Targeted Sequencing Reveals Asian Lung Cancer Variants
- A study published in BMC Cancer highlights the impactful use of targeted next-generation sequencing (NGS) in analyzing Asian non-small-cell lung cancer (NSCLC) variants.
- The study, focused on Taiwanese NSCLC patients, used the Oncomine Focus Assay (OFA) to unravel genetic complexities and improve clinical diagnostics.
- High success rates (80.5%) in sequencing clinical samples emphasize the reliability and efficiency of the OFA platform.
- Performance metrics showcased exceptional on-target alignment (97.0%) and high coverage depths (>500×), ensuring quality genetic data for treatment decisions.
- The study revealed a significant prevalence of pathogenic variants (86.8%), including SNVs, Indels, CNVs, gene fusions, and exon skipping mutations.
- Detection of actionable mutations like EGFR, KRAS, and ALK fusion genes aligns with existing knowledge, validating the assay's utility in therapy selection.
- Identification of rare mutations such as KRAS G12C underscores the importance of comprehensive molecular profiling for potential targeted therapies.
- The study bridges technological innovation with patient care, demonstrating the OFA's clinical value in tailored treatments and resistance monitoring.
- It addresses gaps in NGS platform assessment in NSCLC, emphasizing the need for standardized protocols and inclusive molecular panels for precise oncology.
- The research advocates for the integration of NGS into routine care to enhance therapeutic outcomes and streamline cancer management.
Read Full Article
5 Likes
For uninterrupted reading, download the app